2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists
US8946431B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 16, 2013 |
| Grant date | Feb 3, 2015 |
| Priority date | — |
| Expiry date | Jul 16, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.